Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.58 USD | +2.60% | -7.60% | +3.27% |
Apr. 22 | Transcript : Lexicon Pharmaceuticals, Inc. - Analyst/Investor Day | |
Mar. 25 | Lexicon Pharmaceuticals Files Prospectus for Secondary Offering | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.27% | 379M | C- | ||
-2.31% | 103B | B+ | ||
+0.56% | 95.71B | B+ | ||
+1.69% | 22.02B | B | ||
-17.37% | 20.9B | B+ | ||
-9.30% | 17.85B | A- | ||
-41.01% | 16.21B | A- | ||
-14.85% | 15.52B | B | ||
+3.21% | 13.86B | C+ | ||
+33.54% | 12.04B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LXRX Stock
- Ratings Lexicon Pharmaceuticals, Inc.